Cargando…

The renal phenotype of allopurinol-treated HPRT-deficient mouse

Excess of uric acid is mainly treated with xanthine oxidase (XO) inhibitors, also called uricostatics because they block the conversion of hypoxanthine and xanthine into urate. Normally, accumulation of upstream metabolites is prevented by the hypoxanthine-guanine phosphoribosyltransferase (HPRT) en...

Descripción completa

Detalles Bibliográficos
Autores principales: Zennaro, Cristina, Tonon, Federica, Zarattini, Paola, Clai, Milan, Corbelli, Alessandro, Carraro, Michele, Marchetti, Marialaura, Ronda, Luca, Paredi, Gianluca, Rastaldi, Maria Pia, Percudani, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345830/
https://www.ncbi.nlm.nih.gov/pubmed/28282408
http://dx.doi.org/10.1371/journal.pone.0173512
_version_ 1782513789300637696
author Zennaro, Cristina
Tonon, Federica
Zarattini, Paola
Clai, Milan
Corbelli, Alessandro
Carraro, Michele
Marchetti, Marialaura
Ronda, Luca
Paredi, Gianluca
Rastaldi, Maria Pia
Percudani, Riccardo
author_facet Zennaro, Cristina
Tonon, Federica
Zarattini, Paola
Clai, Milan
Corbelli, Alessandro
Carraro, Michele
Marchetti, Marialaura
Ronda, Luca
Paredi, Gianluca
Rastaldi, Maria Pia
Percudani, Riccardo
author_sort Zennaro, Cristina
collection PubMed
description Excess of uric acid is mainly treated with xanthine oxidase (XO) inhibitors, also called uricostatics because they block the conversion of hypoxanthine and xanthine into urate. Normally, accumulation of upstream metabolites is prevented by the hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme. The recycling pathway, however, is impaired in the presence of HPRT deficiency, as observed in Lesch-Nyhan disease. To gain insights into the consequences of purine accumulation with HPRT deficiency, we investigated the effects of the XO inhibitor allopurinol in Hprt-lacking (HPRT(-/-)) mice. Allopurinol was administered in the drinking water of E12-E14 pregnant mothers at dosages of 150 or 75 μg/ml, and mice sacrificed after weaning. The drug was well tolerated by wild-type animals and heterozygous HPRT(+/-) mice. Instead, a profound alteration of the renal function was observed in the HPRT(-/-) model. Increased hypoxanthine and xanthine concentrations were found in the blood. The kidneys showed a yellowish appearance, diffuse interstitial nephritis, with dilated tubules, inflammatory and fibrotic changes of the interstitium. There were numerous xanthine tubular crystals, as determined by HPLC analysis. Oil red O staining demonstrated lipid accumulation in the same location of xanthine deposits. mRNA analysis showed increased expression of adipogenesis-related molecules as well as profibrotic and proinflammatory pathways. Immunostaining showed numerous monocyte-macrophages and overexpression of alpha-smooth muscle actin in the tubulointerstitium. In vitro, addition of xanthine to tubular cells caused diffuse oil red O positivity and modification of the cell phenotype, with loss of epithelial features and appearance of mesenchymal characteristics, similarly to what was observed in vivo. Our results indicate that in the absence of HPRT, blockade of XO by allopurinol causes rapidly developing renal failure due to xanthine deposition within the mouse kidney. Xanthine seems to be directly involved in promoting lipid accumulation and subsequent phenotype changes of tubular cells, with activation of inflammation and fibrosis.
format Online
Article
Text
id pubmed-5345830
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53458302017-03-30 The renal phenotype of allopurinol-treated HPRT-deficient mouse Zennaro, Cristina Tonon, Federica Zarattini, Paola Clai, Milan Corbelli, Alessandro Carraro, Michele Marchetti, Marialaura Ronda, Luca Paredi, Gianluca Rastaldi, Maria Pia Percudani, Riccardo PLoS One Research Article Excess of uric acid is mainly treated with xanthine oxidase (XO) inhibitors, also called uricostatics because they block the conversion of hypoxanthine and xanthine into urate. Normally, accumulation of upstream metabolites is prevented by the hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme. The recycling pathway, however, is impaired in the presence of HPRT deficiency, as observed in Lesch-Nyhan disease. To gain insights into the consequences of purine accumulation with HPRT deficiency, we investigated the effects of the XO inhibitor allopurinol in Hprt-lacking (HPRT(-/-)) mice. Allopurinol was administered in the drinking water of E12-E14 pregnant mothers at dosages of 150 or 75 μg/ml, and mice sacrificed after weaning. The drug was well tolerated by wild-type animals and heterozygous HPRT(+/-) mice. Instead, a profound alteration of the renal function was observed in the HPRT(-/-) model. Increased hypoxanthine and xanthine concentrations were found in the blood. The kidneys showed a yellowish appearance, diffuse interstitial nephritis, with dilated tubules, inflammatory and fibrotic changes of the interstitium. There were numerous xanthine tubular crystals, as determined by HPLC analysis. Oil red O staining demonstrated lipid accumulation in the same location of xanthine deposits. mRNA analysis showed increased expression of adipogenesis-related molecules as well as profibrotic and proinflammatory pathways. Immunostaining showed numerous monocyte-macrophages and overexpression of alpha-smooth muscle actin in the tubulointerstitium. In vitro, addition of xanthine to tubular cells caused diffuse oil red O positivity and modification of the cell phenotype, with loss of epithelial features and appearance of mesenchymal characteristics, similarly to what was observed in vivo. Our results indicate that in the absence of HPRT, blockade of XO by allopurinol causes rapidly developing renal failure due to xanthine deposition within the mouse kidney. Xanthine seems to be directly involved in promoting lipid accumulation and subsequent phenotype changes of tubular cells, with activation of inflammation and fibrosis. Public Library of Science 2017-03-10 /pmc/articles/PMC5345830/ /pubmed/28282408 http://dx.doi.org/10.1371/journal.pone.0173512 Text en © 2017 Zennaro et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Zennaro, Cristina
Tonon, Federica
Zarattini, Paola
Clai, Milan
Corbelli, Alessandro
Carraro, Michele
Marchetti, Marialaura
Ronda, Luca
Paredi, Gianluca
Rastaldi, Maria Pia
Percudani, Riccardo
The renal phenotype of allopurinol-treated HPRT-deficient mouse
title The renal phenotype of allopurinol-treated HPRT-deficient mouse
title_full The renal phenotype of allopurinol-treated HPRT-deficient mouse
title_fullStr The renal phenotype of allopurinol-treated HPRT-deficient mouse
title_full_unstemmed The renal phenotype of allopurinol-treated HPRT-deficient mouse
title_short The renal phenotype of allopurinol-treated HPRT-deficient mouse
title_sort renal phenotype of allopurinol-treated hprt-deficient mouse
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345830/
https://www.ncbi.nlm.nih.gov/pubmed/28282408
http://dx.doi.org/10.1371/journal.pone.0173512
work_keys_str_mv AT zennarocristina therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT tononfederica therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT zarattinipaola therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT claimilan therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT corbellialessandro therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT carraromichele therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT marchettimarialaura therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT rondaluca therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT paredigianluca therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT rastaldimariapia therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT percudaniriccardo therenalphenotypeofallopurinoltreatedhprtdeficientmouse
AT zennarocristina renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT tononfederica renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT zarattinipaola renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT claimilan renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT corbellialessandro renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT carraromichele renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT marchettimarialaura renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT rondaluca renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT paredigianluca renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT rastaldimariapia renalphenotypeofallopurinoltreatedhprtdeficientmouse
AT percudaniriccardo renalphenotypeofallopurinoltreatedhprtdeficientmouse